Pyridoxine (vitamin B6) therapy for premenstrual syndrome.

[1] Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990;97:922–9. [2] Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 2006;16(Suppl 1):S30–4. [3] Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni A. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997;10:192–7. [4] Andersen ES, Knudsen A, Rix P, Johansen B. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90:109–12. Figure 1 Receiver-operating characteristic (ROC) curve for the evaluation of CA-125 concentration, RMI, and Ferrazzi score in predicting ovarian malignancy in premenopausal women referred for endoscopic management of adnexal masses.